Neurology
-
Randomized Controlled Trial
Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
To determine the effect of erenumab, a human anti-calcitonin gene-related peptide receptor monoclonal antibody, in patients with chronic migraine and medication overuse. ⋯ This study provides Class II evidence that erenumab reduces monthly migraine days at 3 months in patients with chronic migraine and medication overuse.
-
Observational Study
Quantitative EEG predicts outcomes in children after cardiac arrest.
To determine whether quantitative EEG (QEEG) features predict neurologic outcomes in children after cardiac arrest. ⋯ QEEG features can standardize EEG interpretation and predict neurologic outcomes in children after cardiac arrest.
-
Randomized Controlled Trial
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). ⋯ This study provides Class II evidence that for patients with CM, erenumab treatment improves HRQoL, headache impact, and disability.